0000000000222305

AUTHOR

Yury Popov

showing 8 related works from this author

Specific hepatic delivery of procollagen α1(I) small interfering RNA in lipid‐like nanoparticles resolves liver fibrosis

2015

Fibrosis accompanies the wound-healing response to chronic liver injury and is characterized by excessive hepatic collagen accumulation dominated by collagen type I that often progresses to cirrhosis. Here we present ample in-vivo evidence of an up to 90% suppression of procollagen α1(I) expression, a reduction of septa formation and a 40–60% decrease of collagen deposition in mice with progressive and advanced liver fibrosis, that received cationic lipid nanoparticles loaded with small interfering RNA to the procollagen α1(I) gene (LNP-siCol1a1). After intravenous injection up to ninety percent of LNP-siCol1a1 were retained in the liver of fibrotic mice and accumulated in nonparenchymal > …

Pathologymedicine.medical_specialtySmall interfering RNACirrhosisHepatologyRNABiologymedicine.diseaseProcollagen peptidaseFibrosisParenchymamedicineMyofibroblastGeneHepatology
researchProduct

Double-labeled cyclopeptide that bind alpha-v-beta-6 integrin for the quantification of liver fibrogenesis

2018

biologyChemistryIntegrinGastroenterologybiology.proteinAlpha (ethology)Beta (finance)Molecular biologyZeitschrift für Gastroenterologie
researchProduct

Optimized Mouse Models for Liver Fibrosis

2017

Fibrosis is the excessive accumulation of extracellular matrix components due to chronic injury, with collagens as predominant structural components. Liver fibrosis can progress to cirrhosis, which is characterized by a severe distortion of the delicate hepatic vascular architecture, the shunting of the blood supply away from hepatocytes and the resultant functional liver failure. Cirrhosis is associated with a highly increased morbidity and mortality and represents the major hard endpoint in clinical studies of chronic liver diseases. Moreover, cirrhosis is a strong cofactor of primary liver cancer. In vivo models are indispensable tools to study the cellular and molecular mechanisms of li…

0301 basic medicinePathologymedicine.medical_specialtyCirrhosisbusiness.industryLiver fibrosismedicine.diseaseVascular architectureExtracellular matrix03 medical and health scienceschemistry.chemical_compound030104 developmental biology0302 clinical medicinechemistryIn vivoFibrosisMedicine030211 gastroenterology & hepatologyThioacetamidebusinessPrimary liver cancer
researchProduct

Lysyl Oxidase (LOX) Family Members: Rationale and Their Potential as Therapeutic Targets for Liver Fibrosis.

2019

The cross-linking of structural extracellular matrix (ECM) components, especially fibrillar collagens and elastin, is strongly implicated in fibrosis progression and resistance to fibrosis reversal. Lysyl oxidase family members (LOX and LOXL1 [lysyl oxidase-like 1], LOXL2 [lysyl oxidase-like 2], LOXL3 [lysyl oxidase-like 3], and LOXL4 [lysyl oxidase like 4]) are extracellular copper-dependent enzymes that play a key role in ECM cross-linking, but have also other intracellular functions relevant to fibrosis and carcinogenesis. Although the expression of most LOX family members is elevated in experimental liver fibrosis of diverse etiologies, their individual contribution to fibrosis is incom…

0301 basic medicineLiver CirrhosisLysyl oxidaseExtracellular matrixProtein-Lysine 6-Oxidase03 medical and health sciences0302 clinical medicineFibrosisExtracellularmedicineAnimalsHumansLOXL3integumentary systemHepatologyLOXL2biologybusiness.industrymedicine.diseaseenzymes and coenzymes (carbohydrates)030104 developmental biologySimtuzumabCancer researchbiology.protein030211 gastroenterology & hepatologyAmino Acid OxidoreductasesbusinessElastinHepatology (Baltimore, Md.)References
researchProduct

Hepatitis C virus-specific T-cell-derived transforming growth factor beta is associated with slow hepatic fibrogenesis.

2011

Up to 4 million persons in the USA have chronic hepatitis C (CHC) (1). Despite a decline in overall HCV infections, the number of patients with end stage liver disease due to CHC will increase for the next 2 decades (2). Even with highly effective novel therapies, currently 30–50% of infected individuals fail treatment (3). Therefore, a better understanding of mechanisms involved in CHC-related liver disease progression could permit more efficient therapies. Adaptive effector T cells (frequently assessed by measuring production of prototypic T helper 1 cytokine IFNγ) play an important role in control of HCV infection during the acute phase (4). In CHC, effector HCV-specific T cell immune re…

AdultLiver CirrhosisMalemedicine.medical_treatmentT cellGene ExpressionHepacivirusBiologyCD8-Positive T-LymphocytesT-Lymphocytes RegulatoryCollagen Type IArticleInterferon-gammaImmune systemTransforming Growth Factor betamedicineHepatic Stellate CellsCytotoxic T cellHumansIL-2 receptorAgedHepatologyViral Core ProteinsFOXP3Hepatitis C ChronicMiddle AgedInterleukin-10Collagen Type I alpha 1 ChainInterleukin 10Cytokinemedicine.anatomical_structureCross-Sectional StudiesLiverImmunologyDisease ProgressionFemaleMatrix Metalloproteinase 1CD8Hepatology (Baltimore, Md.)
researchProduct

Fibroblast Growth Factor 21 Limits Lipotoxicity by Promoting Hepatic Fatty Acid Activation in Mice on Methionine and Choline-Deficient Diets

2014

Background & Aims Nonalcoholic fatty liver disease is a common consequence of human and rodent obesity. Disruptions in lipid metabolism lead to accumulation of triglycerides and fatty acids, which can promote inflammation and fibrosis and lead to nonalcoholic steatohepatitis. Circulating levels of fibroblast growth factor (FGF)21 increase in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis; therefore, we assessed the role of FGF21 in the progression of murine fatty liver disease, independent of obesity, caused by methionine and choline deficiency. Methods C57BL/6 wild-type and FGF21-knockout (FGF21-KO) mice were placed on methionine- and choline-deficient (MCD)…

Liver Cirrhosismedicine.medical_specialtyTime FactorsBiologyInfusions SubcutaneousSeverity of Illness IndexArticleHepatitischemistry.chemical_compoundAcyl-CoAMethionineNon-alcoholic Fatty Liver DiseaseInternal medicineNonalcoholic fatty liver diseasemedicineAnimalsRNA MessengerMice Knockoutchemistry.chemical_classificationHepatologyFatty acid metabolismFatty AcidsFatty liverGastroenterologyFatty acidmedicine.diseaseRecombinant ProteinsCholine DeficiencyFibroblast Growth FactorsMice Inbred C57BLDisease Models AnimalEndocrinologyLiverchemistryLipotoxicityDisease ProgressionLipid PeroxidationInflammation MediatorsSteatosisLong chain fatty acidOxidation-ReductionGastroenterology
researchProduct

Phosphate Groups in the Lipid A Moiety Determine the Effects of LPS on Hepatic Stellate Cells: A Role for LPS-Dephosphorylating Activity in Liver Fib…

2020

Alkaline phosphatase (AP) activity is highly upregulated in plasma during liver diseases. Previously, we demonstrated that AP is able to detoxify lipopolysaccharide (LPS) by dephosphorylating its lipid A moiety. Because a role of gut-derived LPS in liver fibrogenesis has become evident, we now examined the relevance of phosphate groups in the lipid A moiety in this process. The effects of mono-phosphoryl and di-phosphoryl lipid A (MPLA and DPLA, respectively) were studied in vitro and LPS-dephosphorylating activity was studied in normal and fibrotic mouse and human livers. The effects of intestinal AP were studied in mice with CCL4-induced liver fibrosis. DPLA strongly stimulated fibrogenic…

LipopolysaccharidesLiver CirrhosisMale0301 basic medicinemedicine.medical_specialtyLipopolysaccharideNitric OxideArticleLipid AMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDownregulation and upregulationInternal medicinemedicineAnimalsMacrophagePhosphorylationlipid Alcsh:QH301-705.5liver fibrosisMice Inbred BALB CInterleukin-6MacrophageslipopolysaccharideBiological activityGeneral MedicineIn vitroRatsUp-RegulationRAW 264.7 Cells030104 developmental biologyEndocrinologyLiverchemistrylcsh:Biology (General)Hepatic stellate cellAlkaline phosphatase030211 gastroenterology & hepatologylipids (amino acids peptides and proteins)hepatic stellate cellsalkaline phosphatase
researchProduct

Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease.

2011

Biomarkers are becoming increasingly important in the clinical management of complex diseases, yet our ability to discover new biomarkers remains limited by our dependence on endogenous molecules. Here we describe the development of exogenously administered 'synthetic biomarkers' composed of mass-encoded peptides conjugated to nanoparticles that leverage intrinsic features of human disease and physiology for noninvasive urinary monitoring. These protease-sensitive agents perform three functions in vivo: they target sites of disease, sample dysregulated protease activities and emit mass-encoded reporters into host urine for multiplexed detection by mass spectrometry. Using mouse models of li…

Liver CirrhosisUrinary systemBiomedical EngineeringEarly detectionBioengineeringComputational biologyDiseaseBiology010402 general chemistry01 natural sciencesApplied Microbiology and BiotechnologyMass SpectrometryArticle03 medical and health sciencesMiceIn vivoNeoplasmsmedicineAnimalsHumansAmino Acid SequenceBiomarker discovery030304 developmental biologyMonitoring Physiologic0303 health sciencesCancermedicine.disease3. Good health0104 chemical sciencesDisease Models AnimalBlood biomarkersImmunologyMolecular MedicineNanoparticlesCore biopsyBiomarkersBiotechnologyPeptide HydrolasesNature biotechnology
researchProduct